The Complete Longevity Bloodwork Guide: Every Test Worth Getting and What the Results Mean
Standard annual bloodwork was designed to catch acute illness and gross abnormality, not to optimize the biological trajectory of a healthy adult. The longevity-oriented blood panel is fundamentally different in intent: it is not looking for disease, it is looking for the early patterns that predict disease decades in advance. Here is every test worth ordering, the evidence behind each, the optimal ranges, and how to use the results.
- Standard annual bloodwork misses the most important longevity biomarkers. ApoB (not LDL-C), fasting insulin and HOMA-IR (not just fasting glucose), Lp(a) (which most physicians never order), and hsCRP are among the highest-yield tests that are frequently omitted from standard panels.
- ApoB is the single most important cardiovascular risk biomarker available. Each ApoB particle can penetrate the arterial wall and initiate an atherosclerotic plaque. It is a better predictor of cardiovascular events than LDL-C, non-HDL cholesterol, or any other lipid measure. The longevity target is below 80 mg/dL.
- Fasting insulin and HOMA-IR detect insulin resistance 5 to 15 years before fasting glucose becomes abnormal. Insulin resistance is the most common metabolic abnormality in adults and the upstream driver of type 2 diabetes, cardiovascular disease, NAFLD, and accelerated biological aging.
- Lp(a) is a genetically determined cardiovascular risk factor affecting approximately 20 percent of the population. It is causally linked to atherosclerosis, aortic stenosis, and thrombosis. It cannot be meaningfully modified by lifestyle, making it essential to know early so statin targets can be adjusted accordingly.
- The longevity bloodwork panel should be done annually after age 35, and every 6 months after age 50 or if any biomarker is outside optimal range. Tracking trends over time is more informative than any single data point.
The purpose of longevity bloodwork is fundamentally different from the purpose of standard clinical bloodwork. A standard panel is designed to detect existing disease - diabetes already present, severe anemia already established, thyroid dysfunction already symptomatic. A longevity panel is designed to detect the trajectory toward disease 10, 20, or 30 years before it becomes clinical - when intervention is still fully effective and reversal is possible.1
This requires different tests, different reference ranges, and a different interpretive framework. The standard "normal" range on a laboratory report reflects the distribution of a general, largely unhealthy population - not optimal biology. A fasting glucose of 99 mg/dL is "normal" by standard clinical criteria and represents the early stages of insulin resistance. A LDL of 120 mg/dL is "acceptable" by most guidelines but is associated with ongoing atherosclerotic plaque progression in most adults over 40. Longevity medicine requires precision.
Cardiovascular Risk: The Complete Panel
ApoB - The Most Important Cardiovascular Biomarker
ApolipoproteinB is the structural protein present on every atherogenic lipoprotein particle - VLDL, IDL, LDL, and Lp(a). Each ApoB molecule represents one particle. Unlike LDL-C (which measures cholesterol mass), ApoB measures the number of atherogenic particles directly - and it is particle number, not cholesterol mass, that determines atherosclerotic risk. A small, dense LDL particle carries less cholesterol than a large, buoyant particle but is equally atherogenic (it has the same ApoB count). LDL-C and ApoB can diverge significantly, particularly in insulin-resistant individuals who generate more small dense LDL particles.2
Optimal target: Below 80 mg/dL for most adults. Below 60 mg/dL for high-risk individuals (established cardiovascular disease, diabetes, family history, or elevated Lp(a)). Most major cardiology guidelines now recommend ApoB over LDL-C as the primary target for lipid-lowering therapy.
Lp(a) - The Test Most Physicians Never Order
Lipoprotein(a) is an LDL-like particle with an additional apolipoprotein(a) attached via a disulfide bond. It is genetically determined (80 to 90 percent heritable), largely unmodifiable by lifestyle, and causally linked to atherosclerosis, myocardial infarction, stroke, and aortic valve stenosis. Approximately 20 to 25 percent of the population has Lp(a) above the threshold associated with significantly elevated cardiovascular risk (above 50 mg/dL or 125 nmol/L).3
Why it matters: Because Lp(a) is not on the standard lipid panel, most adults have never had it measured. High Lp(a) carriers are systematically undertreated because their apparent LDL-C may look acceptable while their actual atherogenic particle burden is dangerously elevated. The appropriate response to high Lp(a) is to set more aggressive ApoB targets and to consider statin or PCSK9 inhibitor therapy sooner. RNA therapeutics targeting Lp(a) are in Phase 3 trials as of 2025 - representing the first direct treatment for elevated Lp(a).
Optimal target: Below 30 mg/dL (or 75 nmol/L). Test once - it does not change significantly over time absent major physiological events.
hsCRP - Vascular Inflammation
High-sensitivity C-reactive protein is the most accessible marker of vascular inflammation and a predictor of cardiovascular events independent of LDL-C - the JUPITER trial demonstrated that statin therapy in people with normal LDL but elevated hsCRP significantly reduced MACE, establishing hsCRP as a clinically actionable cardiovascular biomarker.4 It is also a nonspecific marker of general systemic inflammation, making it useful but requiring clinical context (dental infection or a recent cold will transiently elevate hsCRP).
Optimal target: Below 1.0 mg/L. 1 to 3 mg/L is intermediate risk. Above 3 mg/L warrants investigation for sources of chronic inflammation and more aggressive cardiovascular risk reduction.
Metabolic Health: Detecting Insulin Resistance Early
Fasting Insulin and HOMA-IR
Insulin resistance is the most common metabolic abnormality in the developed world, affecting an estimated 40 percent of American adults, and the upstream driver of type 2 diabetes, NAFLD, cardiovascular disease, certain cancers, and accelerated biological aging. Crucially, fasting glucose does not become abnormal until insulin resistance is already advanced - insulin is rising for 5 to 15 years before fasting glucose exceeds the diabetic threshold, as the pancreas compensates by producing more insulin to overcome resistance.5 Fasting insulin and HOMA-IR (homeostatic model assessment of insulin resistance: fasting insulin multiplied by fasting glucose divided by 405) detect this compensated insulin resistance years or decades before fasting glucose becomes diagnostic.
Optimal targets: Fasting insulin below 6 uIU/mL (most labs report "normal" up to 25, which is clinically inadequate for longevity purposes). HOMA-IR below 1.0. Values above 2.0 indicate meaningful insulin resistance warranting dietary, exercise, and lifestyle intervention.
HbA1c and Fasting Glucose
HbA1c reflects average blood glucose over the preceding 3 months and is the standard screen for diabetes and prediabetes. For longevity purposes, the optimal HbA1c is below 5.3 percent - substantially below the clinical normal range maximum of 5.7 percent. A fasting glucose of 85 to 90 mg/dL is associated with the lowest all-cause mortality in prospective studies; values above 95 mg/dL begin to carry meaningfully elevated risk even within the clinical normal range.6
Triglycerides and the TG:HDL Ratio
Fasting triglycerides above 150 mg/dL are an independent cardiovascular risk factor and a reliable proxy for insulin resistance - elevated triglycerides almost always reflect overproduction of VLDL from a liver overwhelmed with dietary sugar and refined carbohydrate. The triglyceride:HDL ratio (in mg/dL units) above 3.0 is a validated surrogate marker for small dense LDL predominance and insulin resistance. The optimal longevity target is triglycerides below 80 mg/dL and TG:HDL ratio below 1.5.
Hormonal Health
Testosterone (Men), Estradiol (Women)
For men over 40: fasting morning total testosterone, free testosterone, LH, FSH, SHBG, and estradiol provide a complete picture of the HPG axis. As discussed in our TRT article, the relevant threshold for total testosterone is 300 to 350 ng/dL, but free testosterone and symptom context are essential for interpretation. For women in perimenopause and beyond: estradiol, FSH, and progesterone levels guide hormone optimization decisions and should be interpreted in the context of symptoms and individual clinical picture.7
Thyroid Function
TSH, free T4, and free T3 should all be measured - not just TSH, which is the standard clinical screen. Subclinical hypothyroidism (elevated TSH with normal T4) and T3 deficiency (low free T3 with normal TSH and T4, often due to impaired T4-to-T3 conversion) are common in middle-aged adults and contribute to fatigue, weight gain, cognitive slowing, and cardiovascular risk that may be missed by TSH alone.8
Metabolic and Nutritional Markers
Homocysteine
Elevated homocysteine is an independent cardiovascular and neurodegenerative risk factor, driven primarily by B vitamin deficiency (B12, B6, folate) and MTHFR gene variants. Optimal homocysteine is below 9 umol/L; above 15 umol/L is associated with substantially elevated risk. Homocysteine is eminently modifiable with appropriate B vitamin supplementation and is one of the most cost-effective longevity tests available.
25-OH Vitamin D
Vitamin D insufficiency affects 40 to 50 percent of the US population and is associated with increased all-cause mortality, cardiovascular disease, cancer risk, immune dysfunction, and cognitive decline in observational studies. Whether supplementation corrects these risks is more controversial than the observational data suggests - the VITAL trial found that vitamin D supplementation did not reduce the primary endpoint of cardiovascular events or cancer, though pre-specified secondary analyses showed benefit in several subgroups. The practical recommendation: test, and if below 40 ng/mL, supplement to achieve 50 to 60 ng/mL.9
Complete Blood Count and Ferritin
A complete blood count identifies anemia, which is under-recognized in older adults and independently associated with cognitive decline, cardiovascular risk, and mortality. Ferritin serves as a marker of iron stores (low ferritin indicates iron deficiency; very high ferritin indicates iron overload or chronic inflammation). Optimal ferritin for longevity is 50 to 150 ng/mL; values above 300 ng/mL in the absence of known inflammation should prompt investigation for hemochromatosis.
The Complete Longevity Panel Summary
| Test | Optimal Longevity Target | Standard Lab Normal | Frequency |
|---|---|---|---|
| ApoB | <80 mg/dL | <130 mg/dL | Annually |
| Lp(a) | <30 mg/dL | Not routinely measured | Once |
| hsCRP | <1.0 mg/L | <3.0 mg/L | Annually |
| Fasting insulin | <6 uIU/mL | <25 uIU/mL | Annually |
| HOMA-IR | <1.0 | <2.5 (clinical) | Annually |
| HbA1c | <5.3% | <5.7% | Annually |
| Triglycerides | <80 mg/dL | <150 mg/dL | Annually |
| Homocysteine | <9 umol/L | <15 umol/L | Annually |
| Vitamin D (25-OH) | 50-60 ng/mL | 30-100 ng/mL | Annually |
| Omega-3 index | >8% | Not routinely measured | Annually |
| Testosterone (men) | >500 ng/dL total; free by age | 300-1000 ng/dL | Annually |
| TSH + free T3/T4 | TSH 1-2.5; T3 upper third of range | TSH 0.5-4.5 | Annually |
| Ferritin | 50-150 ng/mL | 12-300 ng/mL | Annually |
Many primary care physicians will order these tests if asked directly. For tests your physician is reluctant to order (ApoB, Lp(a), fasting insulin), direct-to-consumer lab services (Function Health, Ulta Lab Tests, Boston Heart Diagnostics) allow self-ordering without a physician order in most states. Longevity-oriented physicians and clinics (such as those at Lifespan.io partner clinics, Fountain Life, or independent preventive medicine practices) will typically order the complete panel as routine. Do not accept standard annual bloodwork as sufficient if you are serious about longevity optimization.
References
- 1Attia P. Outlive: The Science and Art of Longevity. Harmony Books, 2023. Chapter 7: The High Price of Ignoring Cholesterol.
- 2Sniderman AD, et al. "Why does LDL-C fail as a marker for residual risk?" Can J Cardiol. 2017;33(3):394-400. [PubMed]
- 3Nordestgaard BG, et al. "Lipoprotein(a) as a cardiovascular risk factor: current status." Eur Heart J. 2010;31(23):2844-2853. [PubMed]
- 4Ridker PM, et al. "Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein (JUPITER)." NEJM. 2008;359(21):2195-2207. [PubMed]
- 5Kraft JR. "Detection of diabetes mellitus in situ (occult diabetes)." Laboratory Medicine. 1975;6(2):10-22. [PubMed]
- 6Khaw KT, et al. "Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk)." BMJ. 2001. [PubMed]
- 7Bhasin S, et al. "Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline." JCEM. 2018. [PubMed]
- 8Garber JR, et al. "Clinical practice guidelines for hypothyroidism in adults: American Association of Clinical Endocrinologists." Endocrine Practice. 2012. [PubMed]
- 9Manson JE, et al. "Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease (VITAL)." NEJM. 2019;380(1):33-44. [PubMed]